Show notes
GERD 6: Pregnancy, Atypical GERD, and the LPR ControversyEpisode keywords: GERD in pregnancy, famotidine pregnancy GERD, LPR laryngopharyngeal reflux controversy, extraesophageal GERD symptoms, PPI safety pregnancy, laryngeal erythema nonspecific, LPS LPRD consensus terminology, empiric PPI atypical symptomsEpisode SummaryTwo-thirds of pregnant women experience heartburn, and the treatment hierarchy is strictly ordered. But the more contentious territory is what happens when reflux is blamed for laryngeal, pharyngeal, and pulmonary symptoms. A recent consensus conference recommended retiring the term "laryngopharyngeal reflux" and replacing it with a framework that separates symptoms from proven disease. Laryngoscopic findings of erythema are found in over 90% of healthy controls, which means the most common tool used to diagnose LPR has essentially no specificity. This episode covers why PPIs do not reliably help extraesophageal symptoms without concurrent typical GERD, and when objective reflux testing is required before treatment.Key TopicsGERD in pregnancy -- step-up approach: Heartburn affects approximately two-thirds of pregnant women. Progesterone relaxes the LES; growing uterus increases intra-abdominal pressure. Treatment order: (1) lifestyle modifications and smaller meals; (2) antacids (aluminum, calcium, magnesium-based are safe) and alginates; (3) sucralfate (not systemically absorbed); (4) H2 receptor antagonists if needed, with famotidine preferred for breastfeeding patients due to lowest breast milk concentration; (5) PPIs as next step if required.PPI safety in pregnancy -- historical category distinction: Under the former FDA letter system, all PPIs were category B except omeprazole, which was category C (animal studies showed some adverse effect without adequate human data). The FDA has since retired letter categories in favor of descriptive labeling, but boards still test this historical distinction. Omeprazole was the sole category C PPI. Esomeprazole strontium and magnesium-containing formulations should be avoided in pregnancy and lactation. Vonoprazan has no adequate pregnancy data; manufacturer advises against breastfeeding while taking it.Atypical and extraesophageal GERD presentations: Chronic laryngitis, chronic cough, asthma exacerbation, globus sensation, sore throat, burning tongue, dental erosions, chronic sinusitis, and non-heartburn chest pain. Two mechanisms: direct contact (acid reaches the larynx, which is far more acid-sensitive than the esophagus) and vagally mediated reflexes (acid in the distal esophagus triggers cough or bronchospasm without reaching the throat).The LPR terminology shift: A recent consensus conference recommends retiring "laryngopharyngeal reflux (LPR)" as a diagnosis. The new framework distinguishes laryngopharyngeal symptoms (LPS, the clinical presentation: cough, voice changes, throat clearing, phlegm sensation) from laryngopharyngeal reflux disease (LPRD, which requires objective evidence that reflux is causing those symptoms). Laryngoscopy cannot establish LPRD.Laryngoscopic findings are nonspecific: Laryngeal erythema and edema attributed to acid damage are found in over 90% of healthy normal controls. A positive laryngoscopy for reflux changes has virtually no specificity. What laryngoscopy does accomplish is excluding other oropharyngeal pathology (vocal cord lesions, masses, structural abnormalities) rather than confirming a reflux etiology.The data problem: Approximately 50% of patients carrying an LPR diagnosis have normal acid exposure on conventional ambulatory pH monitoring. Proximal esophageal and pharyngeal pH monitoring have consistently failed to distinguish suspected LPR patients from healthy controls.PPI response for extraesophageal symptoms: Non-cardiac chest pain with objective evidence of acid reflux responds well (56 to 85% benefit). For throat clearing, hoarseness, and chronic cough without concomitant typical GERD, randomized placebo-controlled trials have not shown consistent PPI benefit over placebo. The AGA advises against empiric PPI trials for extraesophageal symptoms without concomitant typical GERD symptoms. ACG recommends non-GERD causes be evaluated first (ENT for hoarseness, pulmonology and upper airway cough syndrome workup for cough) and reflux testing performed before initiating PPI therapy when typical GERD is absent. When extraesophageal symptoms accompany daily heartburn, an 8 to 12 week trial of twice-daily PPI is reasonable.Surgery for extraesophageal symptoms: Only consider antireflux surgery or endoscopic antireflux procedures in patients with objective evidence of reflux. Fundoplication does not reliably improve laryngopharyngeal symptoms in patients already failing PPI therapy. If PPIs (which dramatically reduce acid) are not helping, acid is likely not the cause, and mechanical prevention of reflux will not help either.Board PearlsHigh-yield: Omeprazole was the only category C PPI under the former FDA system. All others were category B. Boards still test this historical distinction even though the letter system has been retired.Board trap: ENT scopes the larynx and sees erythema, calling it "classic LPR." Laryngoscopic erythema is present in over 90% of healthy controls. This finding cannot diagnose LPRD. Its value is excluding other laryngeal pathology.Board trap: A patient with hoarseness but no heartburn fails a PPI trial. The next step is not fundoplication. The next step is to question the diagnosis and pursue objective reflux testing. Surgery requires proven reflux, and failed PPIs suggest the symptoms may not be acid-related.